Quick Answer
Alzamend Neuro, Inc. reported Cash and Equivalents of $3.95 million for fiscal year 2025.
Alzamend Neuro, Inc. Cash and Equivalents — Annual History
| Fiscal Year | Cash and Equivalents | YoY Change |
|---|---|---|
| 2025 | $3.95M | +950.0% |
| 2024 | $376.0K | -92.7% |
| 2023 | $5.14M | -63.4% |
| 2022 | $14.06M | +629.0% |
| 2021 | $1.93M | +2036.9% |
| 2020 | $90.3K | +111.9% |
| 2019 | $42.6K | — |
Quarterly Cash and Equivalents
| Quarter Ending | Cash and Equivalents | YoY | QoQ |
|---|---|---|---|
| October 31, 2025 | $4.45M | +8.7% | -20.8% |
| July 31, 2025 | $5.62M | +370.8% | +42.3% |
| April 30, 2025 | $3.95M | +950.0% | +17.6% |
| January 31, 2025 | $3.36M | +1087.2% | -18.0% |
| October 31, 2024 | $4.09M | +1945.7% | +242.8% |
| July 31, 2024 | $1.19M | -29.6% | +217.5% |
| April 30, 2024 | $376.0K | -92.7% | +32.9% |
| January 31, 2024 | $282.9K | -96.2% | +41.4% |
- Alzamend Neuro, Inc. showed an increase of +950.0% in Cash and Equivalents compared to the prior fiscal year.
- Over the 2019–2025 period, Alzamend Neuro, Inc.’s cash and equivalents has grown by 9167.8% (from $42.6 thousand to $3.95 million).
- The most recent figure is from Alzamend Neuro, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on July 22, 2025.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: